| Literature DB >> 35902637 |
Ramin Sedaghat Herati1, David A Knorr2,3, Laura A Vella4,5, Luisa Victoria Silva5, Lakshmi Chilukuri3, Sokratis A Apostolidis5,6, Alexander C Huang5,6,7, Alexander Muselman6,8, Sasikanth Manne5,9, Oliva Kuthuru5,9, Ryan P Staupe5, Sharon A Adamski5,9, Senthil Kannan10, Raj K Kurupati10, Hildegund C J Ertl10, Jeffrey L Wong2,3, Stylianos Bournazos2, Suzanne McGettigan6,7, Lynn M Schuchter6,7, Ritesh R Kotecha3, Samuel A Funt3, Martin H Voss3, Robert J Motzer3, Chung-Han Lee3, Dean F Bajorin3, Tara C Mitchell6,7, Jeffrey V Ravetch11, E John Wherry12,13.
Abstract
Anti-programmed death-1 (anti-PD-1) immunotherapy reinvigorates CD8 T cell responses in patients with cancer but PD-1 is also expressed by other immune cells, including follicular helper CD4 T cells (Tfh) which are involved in germinal centre responses. Little is known, however, about the effects of anti-PD-1 immunotherapy on noncancer immune responses in humans. To investigate this question, we examined the impact of anti-PD-1 immunotherapy on the Tfh-B cell axis responding to unrelated viral antigens. Following influenza vaccination, a subset of adults receiving anti-PD-1 had more robust circulating Tfh responses than adults not receiving immunotherapy. PD-1 pathway blockade resulted in transcriptional signatures of increased cellular proliferation in circulating Tfh and responding B cells compared with controls. These latter observations suggest an underlying change in the Tfh-B cell and germinal centre axis in a subset of immunotherapy patients. Together, these results demonstrate dynamic effects of anti-PD-1 therapy on influenza vaccine responses and highlight analytical vaccination as an approach that may reveal underlying immune predisposition to adverse events.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35902637 DOI: 10.1038/s41590-022-01274-3
Source DB: PubMed Journal: Nat Immunol ISSN: 1529-2908 Impact factor: 31.250